Q4 2021 Results

Participants Company overview Pharmaceuticals Financial performance Oncology Innovation: Pipeline overview Novartis submission schedule Supplementary indications for existing brands Financial review Conclusion Appendix Innovation: Clinical trials 2022 2023 2024 2025 ≥2026 Cosentyx LCM canakinumab LCM Adakveo LCM aflibercept BioS Atectura LCM secukinumab, AIN457 ACZ885 SEG101 SOK583 PSA IV Adjuvant NSCLC Sickle cell anaemia with crisis ped Neovascular age-related macular degeneration indacaterol + mometasone, QMF149 Asthma, pediatrics Jakavi ruxolitinib, INC424 Myelofibrosis (combination) LCM Leqvio KJX839 CVRR-LDLC LCM Cosentyx LCM Cosentyx LCM Coartem LCM Beovu LCM Aimovig LCM Kesimpta³ LCM Mayzent4 LCM secukinumab, AIN457 AS H2H secukinumab, AIN457 AS IV artemether + lumefantrine, COA566 Malaria uncompl., formula for <5kg brolucizumab, RTH258 Diabetic retinopathy erenumab, AMG334. ofatumumab siponimod, BAF312 Pediatric Migraine Multiple sclerosis, pediatrics Multiple sclerosis, pediatrics Cosentyx LCM denosumab BioS Cosentyx LCM Cosentyx LCM Cosentyx LCM Kymriah LCM Rydapt LCM secukinumab, AIN457 GP2411 secukinumab, AIN457 secukinumab, AIN457 Hidradenitis suppurativa anti RANKL mAb GCA Lichen Planus secukinumab, AIN457 Lupus Nephritis tisagenlecleucel, CTL019 midostaurin, PKC412 1L high risk ALL, pediatrics & young adults Acute myeloid leukemia, pediatrics Entresto EU1 LCM Kisqali LCM Jakavi LCM Piqray LCM sacubitril/valsartan, LCZ696 ribociclib, LEE011 ruxolitinib, INC424 alpelisib, BYL719 Pediatric CHF HR+/HER2- BC (adj) Pediatrics Acute GVHD HER2+ adv BC Tafinlar + Mekinist LCM Lutathera LCM Jakavi LCM Zolgensma LCM dabrafenib + trametinib, DRB436 177Lu-oxodotreotide² ruxolitinib, INC424 HGG/LGG - Pediatrics GEP-NET 1L G3 Pediatrics Chronic GVHD AVXS-101 OAV101 SMA IT Xolair LCM Piqray LCM Leqvio LCM omalizumab, IGE025 alpelisib, BYL719 KJX839 Auto-injector TNBC Ped Hyperlipidemia Piqray LCM Tafinlar + Mekinist LCM alpelisib, BYL719 Ovarian cancer dabrafenib + trametinib, DRB436 Thyroid cancer Promacta LCM eltrombopag, ETB115 r/r severe aplastic anemia Xolair LCM omalizumab, IGE025 Food allergy 1. Approved in US. 2. 177Lu-dotatate in US. 3. Kesimpta and Mayzent: pediatric study in multiple sclerosis run in conjunction (NEOS). 65 Investor Relations | Q4 2021 Results NOVARTIS | Reimagining Medicine

View entire presentation